Halbgebauer, Steffen
Steinacker, Petra
Riedel, Daniel
Oeckl, Patrick
Anderl-Straub, Sarah
Lombardi, Jolina
von Arnim, Christine A. F.
Nagl, Magdalena
Giese, Armin
Ludolph, Albert C.
Otto, Markus
Funding for this research was provided by:
Intramural funding University of Ulm
EU Joint Programme-Neurodegenerative Diseases networks Genfi-Prox (01ED2008A)
German Federal Ministry of Education and Research (FTLDc 01GI1007A)
EU (Moodmarker) program (01EW2008)
German Research Foundation/DFG (SFB1279)
Foundation of the state Baden-Württemberg (D.3830)
Boehringer Ingelheim Ulm University BioCenter (D.5009)
Thierry Latran Foundation (D.2468)
Martin-Luther-Universität Halle-Wittenberg
Article History
Received: 30 May 2022
Accepted: 8 November 2022
First Online: 22 November 2022
Declarations
:
: All CSF and serum specimens examined in this study were from patients seen in the Departments of Neurology Ulm (between 2010 and 2020) and Göttingen (1997–2003). The study was approved by local Ethics Committees (approval numbers: Ulm 20/10, Göttingen 100305) and conducted following the Declaration of Helsinki. All participants gave their written informed consent to participate in the study.
: Not applicable.
: SH, PS, DR, PO, ML, SAS, JL, AG, and ACL have nothing to report. CFA received honoraria from serving on the scientific advisory board of Biogen, Roche, and Dr. Willmar Schwabe GmbH & Co. KG and has received funding for travel and speaker honoraria from Lilly GmbH, Daiichi Sankyo, Biogen, Roche diagnostics AG, and Dr. Willmar Schwabe GmbH & Co. KG and has received research support from Roche diagnostics AG. MO gave scientific advice for Fujirebio, Roche, Biogen, and Axon.